This report was recently updated on November 16 2024 with the latest and most recent
market numbers
Global Migraine Drugs Market Size, Trends & Analysis - Forecasts to 2026 By Treatment (Acute or Abortive [Triptans, Ergot, Alkaloids, and Others] and Preventive or Prophylactic [Botulinum Toxin, Topiramate, and Others]), By Route of Administration (Oral, Injection, and Others), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); Company Market Share Analysis, End-User Landscape, and Competitor Analysis
Migraine is a category of headache that is intense and permanent, with indications such as phonophobia, blurred vision, and vomiting. Migraine is a common neurovascular disease characterized by painful headaches and is often associated with other neurological symptoms. This disorder is common amongst female demographics and is caused by genetic factors. Moreover, psychological disparities such as stress, depression, terror, enthusiasm, and panic may induce migraine attacks. Thus, opioid therapy aims to relieve the patient's discomfort while also avoiding further attacks. Migraine pain can intensify with exercise, making it impossible for the patient to perform routine and day-to-day tasks.
The migraine drug demand is being driven by an increase in the prominence of migraine attacks globally. Furthermore, a rise in the female population and a boom in patient consciousness about migraine prevention & recovery are key factors driving market development. The migraine medication market is expected to rise at a global level, owing to shifts in lifestyle habits that make people more prone to migraines. Furthermore, rising chronic illness prevalence and growing intake of junk food are expected to drive development in the global migraine drugs market. Growing understanding of migraine amongst the global demographics and the introduction of novel & effective medications is increasing global demand for migraine drugs. Nevertheless, the adverse effects of migraine medications may limit the expansion of the overall migraine drug market in the projected periods to some degree.
Moreover, manufacturers' increasing research & development budgets for the launch of new drugs are expected to provide substantial growth opportunities in the market throughout the forecast period. In order to sustain a steady success level and improve profitability in the forecast period, leading corporations in the migraine drugs market are pursuing various tactics such as technology, acquisition, market partnership, research and development, and so on.
The increasing prevalence of neurological disorders such as migraine in the younger population as a result of a more sedentary lifestyle is expected to boost demand growth throughout the forecast period. Additionally, excessive liquor and oral contraception use increase the likelihood of migraine syndrome. Moreover, evolving technological advances, such as a smartphone-controlled wearable device that incorporates electromagnetic stimulus to relieve migraine pain, are likely to drive the global migraine drugs market further.
Improvements in insurance programs for migraine drugs, as well as the demand for prescription medicines, are driving the market growth. Moreover, the hike in the potential for acceptance of new groups of medicines with higher therapeutic effectiveness in the late-stage portfolio, including the launch of calcitonin gene-related peptide (CGRP) monoclonal antibodies, is boosting market development. Aside from that, the screening of migraine medications for the management of coronavirus disease (COVID-19) is projected to have a favorable impact on consumer development and the global migraine drugs market.
Depending on the type of treatment, the market of migraine drugs is categorized as acute or abortive and preventive or prophylactic. Triptans, ergot, alkaloids, and other substances are categorized as acute or abortive treatments. Botulinum toxin, topiramate, and other drugs are categorized as therapeutic or prophylactic treatments. Acute or abortive treatments hold a significant share in this market because they are available in different shapes and formulations. Abortive therapies are accessible in pill (meds) formulation, nasal powder form, inhaler or fluid, and self-administered infusion or system application. Moreover, they could be used by a patient suffering from a migraine attack with minimal medical supervision. These medications are more powerful than other treatment options in alleviating discomfort and other migraine complications such as vomiting and sound & light intolerance. They are particularly helpful for patients because they function fast.
Depending on the route of administration, the market of migraine drugs is categorized as oral, injection, and others. The oral route of administration held a significant share in this market. Rapid administration of the drug at the appropriate dose in the intensive treatment of migraine can boost efficacy and patient adherence by eliminating migraine cycle continuation. As a result, adequate care should be accessible immediately in a migraine attack. Thus, the nasal is a perfect non-invasive pathway of drug delivery for migraine therapy due to the vast region of absorbent mucous membranes and extensive vascularization in the posterior nasal cavity. Notwithstanding these possible benefits for drug delivery, oral treatments are still by far the most widely used option, which may reflect patient expectations and/or disadvantages of existing ‘non-oral migraine therapies.
As per the geographical analysis, the market can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central South America. North America has been uncovered to lead the global market and is expected to sustain this spot throughout the forecast period. The increasing proliferation of migraines, the growing use of new therapeutics, and a large core demographic in the United States are some of the reasons leading to the region's supremacy. There has also been a slew of experimental therapeutics introduced lately. Furthermore, these drugs and new therapies are being approved by The United States Food and Drug Administration (FDA). The approval is focused on evidence on protection and effectiveness. Many of these aspects contribute to North America's market dominance. Asia-Pacific is presumed to expand significantly in the forecast period pertaining to increased vendor emphasis on developing markets, expanded demand for improved healthcare services, and developments in healthcare services. Moreover, since developed economies are relatively fragmented, this area offers exceptional prospects for venture capitalists and investors.
Allergan Plc, Alder Biopharmaceuticals, Inc., Pfizer Inc., GlaxoSmithKline Plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc,Johnson & Johnson, Amgen Inc., Eli Lilly and Company, eNeura Inc., amongst others, are the major players in the migraine drugs market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview And Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Global Migraine Drugs Industry Overview, 2019-2026
2.1.1 Industry Overview
2.1.2 Treatment Overview
2.1.3 Route of Administration Overview
2.1.4 Regional Overview
Chapter 3 Global Migraine Drugs Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2019-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Increasing Healthcare Expenditure
3.3.1.2 Growing Awareness Programs Regarding Prevention & Treatment of Migraine
3.3.2 Industry Challenges
3.3.2.1 Side-Effects of Medications Prescribed for Migraine
3.4 Prospective Growth Scenario
3.4.1 Treatment Growth Scenario
3.4.2 Route of Administration Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Global Migraine Drugs Market, By Treatment
4.1 Treatment Outlook
4.2 Acute or Abortive
4.2.1 Market Size, By Region, 2019-2026 (USD Million)
4.3 Preventive or Prophylactic
4.3.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 5 Global Migraine Drugs Market, By Route of Administration
5.1 Route of Administration Outlook
5.2 Oral
5.2.1 Market Size, By Region, 2019-2026 (USD Million)
5.3 Injection
5.3.1 Market Size, By Region, 2019-2026 (USD Million)
5.4 Others
5.4.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 6 Global Migraine Drugs Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2019-2026 (USD Million)
6.2.2 Market Size, By Treatment, 2019-2026 (USD Million)
6.2.3 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.2.4 U.S.
6.2.4.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.2.4.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.2.5 Canada
6.2.5.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.2.5.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2019-2026 (USD Million)
6.3.2 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.3 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.4 Germany
6.2.4.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.2.4.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.5 UK
6.3.5.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.5.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.6 France
6.3.6.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.6.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.7 Italy
6.3.7.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.7.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.8 Spain
6.3.8.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.8.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.9 Russia
6.3.9.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.3.9.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2019-2026 (USD Million)
6.4.2 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.3 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.4.4 China
6.4.4.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.4.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.4.5 India
6.4.5.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.5.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.4.6 Japan
6.4.6.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.6.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.4.7 Australia
6.4.7.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.7.2 Market size, By Route of Administration, 2019-2026 (USD Million)
6.4.8 South Korea
6.4.8.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.4.8.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2019-2026 (USD Million)
6.5.2 Market Size, By Treatment, 2019-2026 (USD Million)
6.5.3 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.5.4 Brazil
6.5.4.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.5.4.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.5.5 Mexico
6.5.5.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.5.5.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.5.6 Argentina
6.5.6.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.5.6.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2019-2026 (USD Million)
6.6.2 Market Size, By Treatment, 2019-2026 (USD Million)
6.6.3 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.6.4.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.6.5 UAE
6.6.5.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.6.5.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.6.6 South Africa
6.6.6.1 Market Size, By Treatment, 2019-2026 (USD Million)
6.6.6.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 Allergan Plc
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info Graphic Analysis
7.3 Alder Biopharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info Graphic Analysis
7.4 Pfizer Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info Graphic Analysis
7.5 GlaxoSmithKline Plc
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info Graphic Analysis
7.6 Merck & Co. Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info Graphic Analysis
7.7 Teva Pharmaceutical Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info Graphic Analysis
7.8 AstraZeneca Plc
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info Graphic Analysis
7.9 Johnson & Johnson
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info Graphic Analysis
7.10 Amgen Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info Graphic Analysis
7.11 Eli Lilly and Company
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info Graphic Analysis
7.12 eNeura Inc.
7.12.1 Company Overview
7.12.2 Financial Analysis
7.12.3 Strategic Positioning
7.12.4 Info Graphic Analysis
7.13 Other Companies
7.13.1 Company Overview
7.13.2 Financial Analysis
7.13.3 Strategic Positioning
7.13.4 Info Graphic Analysis
The Global Migraine Drugs Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Migraine Drugs Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
![Global Migraine Drugs Market Size, Trends & Analysis - Forecasts to 2026 By Treatment (Acute or Abortive [Triptans, Ergot, Alkaloids, and Others] and Preventive or Prophylactic [Botulinum Toxin, Topiramate, and Others]), By Route of Administration (Oral, Injection, and Others), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); Company Market Share Analysis, End-User Landscape, and Competitor Analysis](https://www.globalmarketestimates.com/images/cat/Healthcare.png)
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
